Stonepine Capital Management’s Neos Therapeutics, Inc NEOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-4,962,657
| Closed | -$3.1M | – | 35 |
|
|
2020
Q4 | $3.1M | Buy |
4,962,657
+578,458
| +13% | +$357K | 2.37% | 15 |
|
|
2020
Q3 | $2.33M | Sell |
4,384,199
-62,827
| -1% | -$42.7K | 2.42% | 12 |
|
|
2020
Q2 | $3.05M | Sell |
4,447,026
-243,120
| -5% | -$193K | 5.9% | 6 |
|
|
2020
Q1 | $3.52M | Sell |
4,690,146
-168,743
| -3% | -$232K | 3.72% | 10 |
|
|
2019
Q4 | $7.34M | Buy |
4,858,889
+356,588
| +8% | +$535K | 5.11% | 6 |
|
|
2019
Q3 | $6.66M | Sell |
4,502,301
-468,713
| -9% | -$759K | 6.47% | 5 |
|
|
2019
Q2 | $6.41M | Buy |
4,971,014
+459,510
| +10% | +$845K | 4.42% | 7 |
|
|
2019
Q1 | $11.8M | Buy |
4,511,504
+301,351
| +7% | +$707K | 6.77% | 4 |
|
|
2018
Q4 | $6.95M | Buy |
4,210,153
+3,982,234
| +1,747% | +$11.2M | 6.1% | 6 |
|
|
2018
Q3 | $1.1M | Buy |
+227,919
| New | +$1.29M | 0.65% | 26 |
|
|
2018
Q1 | – | Sell |
-140,000
| Closed | -$1.43M | – | 40 |
|
|
2017
Q4 | $1.43M | Buy |
+140,000
| New | +$1.34M | 0.86% | 21 |
|
|
2017
Q3 | – | Sell |
-565,100
| Closed | -$4.13M | – | 28 |
|
|
2017
Q2 | $4.13M | Buy |
+565,100
| New | +$4.27M | 2.23% | 17 |
|
Stonepine Capital Management's NEOS Position: Q1 2021 in Review
Stonepine Capital Management sold out of Neos Therapeutics, Inc (NEOS) in Q1 2021, closing a stake of 4,962,657 shares — an estimated $3.1M sold.
Stonepine Capital Management first reported a position in NEOS in Q2 2017 and held it in 12 quarters. The position peaked at $11.8M in Q1 2019. 0 funds tracked by Wall St. Rank hold NEOS as of Q1 2021.
- Stonepine Capital Management reported no remaining Neos Therapeutics, Inc position as of Q1 2021 after selling out during the quarter.
- Stonepine Capital Management sold 4,962,657 Neos Therapeutics, Inc shares in Q1 2021, an estimated $3.1M.
- Stonepine Capital Management first reported a position in Neos Therapeutics, Inc in Q2 2017 and held it in 12 quarters.
- Stonepine Capital Management's Neos Therapeutics, Inc position peaked at $11.8M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q1 2021.
Based on Stonepine Capital Management's 13F filing for Q1 2021, filed 14 May 2021.